|
1
|
Ludwig H, Novis Durie S, Meckl A, Hinke A
and Durie B: Multiple Myeloma incidence and mortality around the
globe; Interrelations between health access and quality, economic
resources, and patient empowerment. Oncologist. 25:e1406–e1413.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eisfeld C, Kajüter H, Möller L, Wellmann
I, Shumilov E and Stang A: Time trends in survival and causes of
death in multiple myeloma: A population-based study from Germany.
BMC Cancer. 23:3172023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rajkumar SV: Multiple myeloma: 2022 update
on diagnosis, risk stratification, and management. Am J Hematol.
97:1086–1107. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katagiri T and Watabe T: Bone
morphogenetic proteins. Cold Spring Harb Perspect Biol.
8:a0218992016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bragdon B, Moseychuk O, Saldanha S, King
D, Julian J and Nohe A: Bone morphogenetic proteins: A critical
review. Cell Signal. 23:609–620. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grcević D, Kusec R, Kovacić N, Lukić A,
Lukić IK, Ivcević S, Nemet D, Seiwerth RS, Ostojić SK, Croucher PI
and Marusić A: Bone morphogenetic proteins and receptors are
over-expressed in bone-marrow cells of multiple myeloma patients
and support myeloma cells by inducing ID genes. Leuk Res.
34:742–751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seckinger A, Meissner T, Moreaux J,
Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy
JD Jr, Barlogie B, et al: Bone morphogenic protein 6: A member of a
novel class of prognostic factors expressed by normal and malignant
plasma cells inhibiting proliferation and angiogenesis. Oncogene.
28:3866–3879. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Olsen OE, Wader KF, Misund K, Våtsveen TK,
Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, et al:
Bone morphogenetic protein-9 suppresses growth of myeloma cells by
signaling through ALK2 but is inhibited by endoglin. Blood Cancer
J. 4:1962014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maes K, Nemeth E, Roodman GD, Huston A,
Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys
L, Rivera S, et al: In anemia of multiple myeloma, hepcidin is
induced by increased bone morphogenetic protein 2. Blood.
116:3635–3644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu CK, Wei MT, Wu HC, Wu CL, Wu CJ, Liaw H
and Su WP: BMP2 promotes lung adenocarcinoma metastasis through BMP
receptor 2-mediated SMAD1/5 activation. Sci Rep. 12:163102022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raida M, Clement JH, Leek RD, Ameri K,
Bicknell R, Niederwieser D and Harris AL: Bone morphogenetic
protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res
Clin Oncol. 131:741–750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du J, Yang S, Wang Z, Zhai C, Yuan W, Lei
R, Zhang J and Zhu T: Bone morphogenetic protein 6 inhibit
stress-induced breast cancer cells apoptosis via both Smad and p38
pathways. J Cell Biochem. 103:1584–1597. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stieglitz D, Lamm S, Braig S, Feuerer L,
Kuphal S, Dietrich P, Arndt S, Echtenacher B, Hellerbrand C, Karrer
S and Bosserhoff AK: BMP6-induced modulation of the tumor
micro-milieu. Oncogene. 38:609–621. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, et al: International Myeloma Working Group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:538–548. 2014. View Article : Google Scholar
|
|
15
|
Fleige S and Pfaffl MW: RNA integrity and
the effect on the real-time qRT-PCR performance. Mol Aspects Med.
27:126–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giraldo-Parra L, Ramirez LG, Navas A and
Gómez MA: Quality parameters for RNA preparations from biopsies of
ulcerated human skin. Wellcome Open Res. 28:2492023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okamoto T and Okabe S: Ultraviolet
absorbance at 260 and 280 nm in RNA measurement is dependent on
measurement solution. Int J Mol Med. 5:657–659. 2000.PubMed/NCBI
|
|
18
|
Pinto FL, Thapper A, Sontheim W and
Lindblad P: Analysis of current and alternative phenol based RNA
extraction methodologies for cyanobacteria. BMC Mol Biol. 7:792009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilfinger WW, Mackey K and Chomczynski P:
Effect of pH and ionic strength on the spectrophotometric
assessment of nucleic acid purity. Biotechniques. 22:478–481. 1997.
View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ebisawa T, Tada K, Kitajima I, Tojo K,
Sampath TK, Kawabata M, Miyazono K and Imamura T: Characterization
of bone morphogenetic protein-6 signaling pathways in osteoblast
differentiation. J Cell Sci. 112:3519–27. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu H, Tong G, Yan T, Dong L, Yang X, Dou
D, Sun Z, Liu T, Zheng X, Yang J, et al: Transcriptomic analysis
provides insights to reveal the bmp6 function related to the
development of intermuscular bones in zebrafish. Front Cell Dev
Biol. 10:8214712022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhan F, Huang Y, Colla S, Stewart JP,
Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B,
et al: The molecular classification of multiple myeloma. Blood.
108:2020–2028. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fonseca R, Bergsagel PL, Drach J,
Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi
M, Minvielle S, et al: International myeloma working group.
International myeloma working group molecular classification of
multiple myeloma: spotlight review. Leukemia. 23:2210–2221. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matsuzaki Y, Umemoto T, Tanaka Y, Okano T
and Yamato M: β2-Microglobulin is an appropriate reference gene for
RT-PCR-based gene expression analysis of hematopoietic stem cells.
Regen Ther. 23:91–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sabbir H: Validation of internal control
genes for quantitative real-time PCR under different experiment
conditions in Multiple Myeloma. J Bio Sci Biotechnol. 7:79–90.
2019.
|
|
27
|
Nazari F, Parham A and Maleki AF: GAPDH,
β-actin and β2-microglobulin, as three common reference genes, are
not reliable for gene expression studies in equine adipose- and
marrow-derived mesenchymal stem cells. J Anim Sci Technol.
57:182015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin J and Redies C: Histological evidence:
Housekeeping genes beta-actin and GAPDH are of limited value for
normalization of gene expression. Dev Genes Evol. 222:369–376.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bach DH, Park HJ and Lee SK: The dual role
of bone morphogenetic proteins in cancer. Mol Ther Oncolytics.
8:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ro TB, Holt RU, Brenne AT, Hjorth-Hansen
H, Waage A, Hjertner O, Sundan A and Borset M: Bone morphogenetic
protein-5, −6 and −7 inhibit growth and induce apoptosis in human
myeloma cells. Oncogene. 23:3024–3032. 2004. View Article : Google Scholar : PubMed/NCBI
|
